Previous Close | 0.4438 |
Open | 0.4500 |
Bid | 0.5363 x 1100 |
Ask | 0.5425 x 1000 |
Day's Range | 0.4260 - 0.4889 |
52 Week Range | 0.4260 - 2.3200 |
Volume | |
Avg. Volume | 7,087,856 |
Market Cap | 227.406M |
Beta (5Y Monthly) | 1.29 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.1100 |
Earnings Date | May 26, 2024 - May 30, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.43 |
Subscribe to Yahoo Finance Plus to view Fair Value for ME
23andMe customers can now gain deeper insight into their likelihood of developing breast, colorectal, and prostate cancer through new reports based on polygenic risk scores (PRS) developed by 23andMeSOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, released three new genetic reports for 23andMe+ members on breast, colorectal and prostate cancer. The reports are based on statistical models know
23andMe to give an oral presentation on the genetic signature of ULBP6, the target of 23ME-01473, along with poster presentations of the biology of ULBP6 and mechanism of 23ME-01473, and new non-clinical insights for 23ME-00610, targeting the CD200R1 pathwaySOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral presentation and two poster presentations on two of
In this article, we will be taking a look at the 20 most valuable digital health companies in the US. If you are not interested in reading about the global health market, head straight to the 5 Most Valuable Digital Health Companies In The US. As of the latest data, several digital health companies stand […]